

Ceann Feidhme/Seitbhíse, Seirbhísí agus Scéimeanna Náisiúnta

Oifig Uimh. 3, Coimpléasc Oifige Chill Chríona, Chill Chainnigh

Head of Function/Service National Services & Schemes

@hselive

www.hse.ie

Health Service Executive, Office No. 3, t 087 2668759 Kilcreene, Kilkenny

e catherinet.donohoe@hse.ie

Deputy Aindrias Moynihan Dáil Eireann Leinster House Dublin 2

24th July 2025

PQ:

42438/25

To ask the Minister for Health the total expenditure on the Cross-Border Directive for each of the years 2023 to 2024, and to date in 2025; the number of patients treated under the Cross-Border Directive in each of the years 2023 to 2024, and to date in 2025, in tabular form; and if she will make a statement on the matter. -Aindrias Moynihan

Dear Deputy Moynihan,

Thank you for your parliamentary question referenced above, which was passed to the HSE for response. I am setting out hereunder the information requested. Please note the information being provided is in respect of the number of applications processed as opposed to the number of patients. We record data in terms of application hence I am unable to provide this data specific to patients. One patient may use the provisions of the Directive on more than one occasion.

Activity Description	2023	2024	June Year to Date
			2025
No. of	1,762	2,266	1,067
reimbursements			
processed*			
Value of claims	€9,002,407	€11,879,286	€5,956,086
Processed			

^{*}This figure is the actual number of reimbursements processed for payment. Each reimbursement may include both consultations and treatment but is treated as a single reimbursement.

In general the Cross Border Directive (CBD) allows public patients to access healthcare in another EU/EEA country which they are entitled to access in Ireland. The patient pays for the treatment up front and claims reimbursement upon return to Ireland. Reimbursement is at the cost of the treatment abroad



or the cost of the treatment in Ireland whichever is the lesser. Public patient pathways as they apply to accessing the healthcare in Ireland equally apply to accessing the healthcare abroad under the CBD.

The HSE continues to work to make patients aware of their rights and entitlements to use the provisions of the Directive and this is reflected in the steady increase in the number of patients exercising their rights since the introduction of the scheme in 2014.

I trust this is of assistance.

Yours sincerely,

Catherine Donohoe — Head of Function/Service